Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.21 Insider Own45.17% Shs Outstand9.67M Perf Week-7.69%
Market Cap6.96M Forward P/E- EPS next Y-1.73 Insider Trans0.00% Shs Float5.30M Perf Month-5.26%
Income-15.96M PEG- EPS next Q-0.43 Inst Own1.46% Short Float5.58% Perf Quarter-25.77%
Sales0.48M P/S14.51 EPS this Y56.74% Inst Trans-56.53% Short Ratio0.71 Perf Half Y-33.94%
Book/sh0.27 P/B2.64 EPS next Y-16.95% ROA-45.61% Short Interest0.30M Perf Year-92.76%
Cash/sh2.51 P/C0.29 EPS next 5Y- ROE-59.52% 52W Range0.51 - 10.84 Perf YTD-61.90%
Dividend Est.- P/FCF- EPS past 5Y-2.40% ROI-82.94% 52W High-93.36% Beta1.00
Dividend TTM- Quick Ratio4.63 Sales past 5Y- Gross Margin86.49% 52W Low42.52% ATR (14)0.08
Dividend Ex-Date- Current Ratio4.63 EPS Y/Y TTM56.38% Oper. Margin-3398.54% RSI (14)50.78 Volatility6.31% 10.67%
Employees- Debt/Eq0.00 Sales Y/Y TTM-15.91% Profit Margin-3317.05% Recom1.00 Target Price7.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q90.81% Payout- Rel Volume0.07 Prev Close0.71
Sales Surprise- EPS Surprise-3.85% Sales Q/Q-100.00% EarningsMay 16 Avg Volume418.80K Price0.72
SMA2012.06% SMA50-14.15% SMA200-64.43% Trades Volume30,009 Change1.90%
Date Action Analyst Rating Change Price Target Change
Jul-20-22Downgrade Oppenheimer Outperform → Perform
Jul-20-22Downgrade H.C. Wainwright Buy → Neutral
Jul-18-22Resumed Oppenheimer Outperform $5.50
Apr-28-22Initiated Chardan Capital Markets Buy $5
May-18-21Initiated Guggenheim Buy $7
Jun-27-19Initiated Oppenheimer Outperform
Mar-09-18Downgrade Chardan Capital Markets Buy → Neutral $25 → $3
Mar-08-18Downgrade Piper Jaffray Overweight → Neutral
Mar-08-18Downgrade H.C. Wainwright Buy → Neutral $3
Nov-06-17Reiterated Chardan Capital Markets Buy $20 → $25
May-24-24 09:55AM
May-16-24 11:53AM
May-13-24 07:23AM
May-09-24 04:05PM
12:00PM Loading…
Apr-19-24 12:00PM
Apr-12-24 01:53PM
Apr-09-24 05:15PM
Apr-08-24 12:00PM
Mar-05-24 04:35PM
Feb-22-24 08:00AM
Dec-18-23 08:00AM
Dec-13-23 12:00PM
Dec-11-23 12:00PM
04:30PM Loading…
Dec-04-23 04:30PM
Nov-14-23 04:15PM
Nov-09-23 04:05PM
Oct-16-23 01:01PM
Oct-12-23 09:00AM
Oct-04-23 08:00AM
Sep-06-23 08:00AM
Aug-14-23 08:28AM
May-15-23 06:08PM
Mar-17-23 06:37AM
Mar-14-23 08:00AM
Mar-09-23 08:00AM
Feb-23-23 07:00AM
08:00AM Loading…
Feb-16-23 08:00AM
Nov-29-22 05:43PM
Nov-14-22 07:55PM
Nov-10-22 05:35PM
Sep-02-22 12:36PM
Sep-01-22 04:30PM
Aug-15-22 05:35PM
Aug-08-22 10:00AM
Aug-02-22 08:00AM
Jul-21-22 11:49AM
Jul-20-22 07:35AM
Jul-19-22 04:01PM
May-31-22 08:00AM
May-17-22 08:15AM
May-16-22 08:15AM
May-12-22 05:45PM
May-10-22 08:00AM
May-08-22 10:51AM
May-04-22 07:55AM
May-03-22 08:55AM
Apr-28-22 04:05PM
Apr-26-22 08:00AM
Apr-01-22 08:36AM
Mar-31-22 08:00AM
Mar-24-22 03:04PM
Mar-23-22 09:25AM
Mar-14-22 09:57AM
Mar-08-22 08:00AM
Mar-03-22 08:00AM
Mar-01-22 05:45PM
Feb-15-22 04:05PM
Feb-02-22 08:00AM
Jan-18-22 08:00AM
Jan-06-22 08:10AM
Dec-28-21 09:19AM
Dec-20-21 07:30AM
Dec-09-21 11:18AM
Dec-07-21 10:26AM
Nov-22-21 10:48AM
Nov-18-21 12:00PM
Nov-15-21 12:25PM
Nov-08-21 03:00PM
Oct-05-21 08:00AM
Sep-17-21 07:00AM
Sep-10-21 07:00AM
Aug-30-21 07:00AM
Aug-23-21 01:55PM
Aug-16-21 08:25AM
Aug-06-21 10:20AM
Aug-05-21 03:01PM
Jul-08-21 07:00AM
Jun-20-21 02:02PM
Jun-17-21 02:51PM
Jun-16-21 05:00AM
Jun-15-21 07:00AM
Jun-03-21 07:00AM
May-20-21 07:00AM
May-11-21 08:35AM
Notable Labs Ltd. is a clinical-stage platform therapeutics company that develops predictive medicines for patients with cancer. Through its proprietary Predictive Medicines Platform, the firm predicts whether or not that patient is likely to respond to that specific therapeutic. The company's Predictive Medicines Platform is designed to identify and select patients expected to be clinically responsive prior to their treatment to improve patient outcomes and fast-track clinical development. The firm's product candidate, Volasertib, is a Polo-like Kinase 1 inhibitor. Notable Labs was founded on January 31, 2000 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FR Capital Holdings, L.P.Former 10% OwnerJan 02 '24Sale1.8950,00094,670880,489Jan 03 05:00 PM
FR Capital Holdings, L.P.10% OwnerDec 29 '23Sale1.836,00010,990930,489Jan 02 05:00 PM
FR Capital Holdings, L.P.10% OwnerDec 28 '23Sale2.0121,50043,146936,489Jan 02 05:00 PM
FR Capital Holdings, L.P.10% OwnerDec 27 '23Sale2.0820,03341,695957,989Dec 28 05:00 PM
FR Capital Holdings, L.P.10% OwnerDec 26 '23Sale2.1611,45624,766978,022Dec 28 05:00 PM
FR Capital Holdings, L.P.10% OwnerDec 22 '23Sale2.4145,000108,284989,478Dec 26 05:00 PM
FR Capital Holdings, L.P.10% OwnerDec 21 '23Sale2.512,8677,1911,034,478Dec 26 05:00 PM